公司资料
Protagonist Therapeutics Inc 股价、新闻与催化剂
- 股票代码:
- PTGX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
158.62 USD (+2.27%)
收盘价
最后更新: 2026年8月17日
6B USD
市值
股价为何变动
As of Aug 17, 2026, PTGX closed up 2.27% at $158.62. No new same-company headline was identified in the current news window.
公司概览
业务概览
Protagonist Therapeutics is a biotechnology company focused on peptide-based medicines and inflammatory disease. Its story is built around using peptide chemistry and targeted biology to address immune-mediated disorders.
所在地与行业分类
Protagonist is headquartered in the United States and listed on NASDAQ. It sits in specialty immunology biotechnology.
商业模式特征
The company depends on clinical validation, partnership strategy, and the ability to create value from a focused pipeline. Investors watch data, launch prospects, and strategic updates.
生物医药行业定位
Protagonist occupies a premium peptide-immunology niche within biotech. It has meaningful platform depth, but remains sensitive to clinical and partnership milestones.
未来催化剂
- Protagonist's catalysts are icotrokinra and the broader inflammatory-disease pipeline, where clinical and regulatory updates can materially move the stock. The company remains highly data-sensitive.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。